All In Biotech

Drug Trial Radar · NCT07510828

PRISM-NK: Precision-Matched Allogeneic Single- or Dual-Target CAR-NK Cells for Advanced Solid Tumors

A Phase 1/2 Biomarker-Guided Platform Study of Allogeneic Donor-Derived Single-Target or Dual-Target CAR-NK Cell Therapy Selected by Tumor Antigen Profiling (Liquid Biopsy and/or Tissue Biopsy) in Participants With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Mar 2, 2026

Primary completion

Mar 14, 2027

Study completion Apr 17, 2028

Sponsor

Lead sponsor
Beijing BiotechIndustry
Sponsor type
Industry
First posted
Apr 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2, open-label, biomarker-guided platform study evaluates the safety, tolerability, and preliminary anti-tumor activity of banked allogeneic donor-derived chimeric antigen receptor natural killer (CAR-NK) cells in adults with advanced solid tumors. During screening, tumor antigen profiling is performed using tissue biopsy and/or liquid biopsy (circulating tumor DNA and/or circulating tumor cells). Participants are assigned to receive either a single-target CAR-NK product (matched to the dominant tumor antigen) or a dual-target CAR-NK product (matched to two co-expressed antigens) to reduce the risk of antigen escape.

Conditions

  • Advanced or Metastatic Solid Tumors

Interventions

  • EB-PT-CAR-NK-SBiological

    single-target CAR-NK cell infusion, IV

  • EB-PT-CAR-NK-DBiological

    dual-target CAR-NK cell infusion, IV

  • Lymphodepleting chemotherapyDrug

    fludarabine + cyclophosphamide

  • Cytokine supportDrug

    low-dose IL-2 or IL-15 agonist

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose- limiting toxicitiesTime frame: 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Shenzhen Hospital

    Shenzhen, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.